This presentation is part of a series of webinars on 505(b)(2) NDA drug development that highlights the diversity, simplicity, and complexity of the 505(b)(2) application process. This session focuses on the five pillars for successful 505(b)(2) product development: science, regulatory, medical, commercial and legal/IP/business.
Speaker:
William Salminen, PhD, DABT, PMP, Vice President, Nonclinical Safety and Toxicology
View the other webinars in the series here:
Ready to get started? So are we.
Drop us a line to learn more about how we can help.